mcrpc - Robuta Search

https://stanfordhealthcare.org/trials/s/NCT04446117.html Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. study cabozantinib combination atezolizumab versus https://www.onclive.com/view/dr-wise-on-the-importance-of-genetic-testing-in-mcrpc Dr Wise on the Importance of Genetic Testing in mCRPC | OncLive Oct 16, 2026 - David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need... on the genetic testing wise importance mcrpc https://www.urologytimes.com/view/study-supports-safety-of-darolutamide-cabazitaxel-combination-in-mcrpc Study supports safety of darolutamide/cabazitaxel combination in mCRPC | Urology Times Oct 10, 2026 - “Darolutamide, unlike enzalutamide, does not affect cabazitaxel systemic exposure, justifying their use in combination,” the authors wrote in their poster. urology times study supports safety darolutamide Sponsored https://www.sexygamerz.com/enter.php?prg=1&id=robuta&t=best&ad_id=sexygamerz_315x300_default2.jpg Sexy Gamerz - World's Best Gamer Dating Tired of playing alone? Find a hot gamer girl on Sexy Gamerz. https://www.targetedonc.com/view/genomic-testing-in-mcrpc Genomic Testing in mCRPC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Oct 11, 2026 - An expert emphasizes that genomic profiling—including both germline and somatic testing—is now essential in metastatic prostate cancer management because it... genomic testing mcrpc targeted oncology immunotherapy https://www.urologytimes.com/view/potential-use-of-parp-inhibitors-for-first-line-treatment-of-mcrpc Potential Use of PARP Inhibitors for First-Line Treatment of mCRPC | Urology Times Oct 14, 2026 - A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC. first line treatment parp inhibitors urology times potential use https://stanfordhealthcare.org/trials/1/NCT04825652.html 177Lu-PSMA-617 Managed Access Program for mCRPC Patients Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. managed access program psma mcrpc patients https://ascopost.com/issues/may-25-2026/combination-enzalutamide-and-radium-223-extends-overall-survival-in-bone-dominant-mcrpc/ Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC - The ASCO... In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor... overall survival combination enzalutamide radium extends https://www.clinicaltrialsarena.com/news/pfizers-talzenna-gains-14-months-os-lead-over-mcrpc-soc/ Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC - Clinical Trials Arena Feb 14, 2025 - Results from the company’s Talapro-2 prostate cancer trial saw a 38% reduction in the risk of death among HRR-mutated patients. clinical trials talzenna gains months lead